Swinging the vote for rapamycin.
Novak
Kristine
K
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D016228:Endothelial Growth Factors / Q000378:metabolism; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D036341:Intercellular Signaling Peptides and Proteins / Q000378:metabolism; D007376:Interleukin-2 / Q000378:metabolism; D008222:Lymphokines / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D020123:Sirolimus / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D007166:Immunosuppressive Agents; D036341:Intercellular Signaling Peptides and Proteins; D007376:Interleukin-2; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020123:Sirolimus